Teijin Pharma Limited has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for YORVIPATH® (palopegteriparatide), a novel treatment for adults with hypoparathyroidism. The approval followed positive results from a Phase III clinical trial conducted by Ascendis Pharma in Japan. YORVIPATH® was subsequently listed on the National Health Insurance price list in October 2025 and launched on November 6, 2025. The drug, licensed from Ascendis Pharma A/S, has also been designated as an orphan drug in Japan, the United States, and Europe.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.